Neumora Therapeutics (NASDAQ:NMRA) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a report released on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $8.00 price target on the stock.

A number of other research firms have also recently issued reports on NMRA. Royal Bank Of Canada raised Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $4.00 to $7.00 in a research report on Monday, December 1st. Mizuho set a $6.00 price target on Neumora Therapeutics in a research note on Monday, January 5th. William Blair raised Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. Finally, Leerink Partners assumed coverage on shares of Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.71.

Neumora Therapeutics Stock Up 1.0%

Shares of NMRA stock opened at $1.95 on Tuesday. Neumora Therapeutics has a 52-week low of $0.61 and a 52-week high of $3.65. The stock has a market cap of $325.83 million, a price-to-earnings ratio of -1.34 and a beta of 2.49. The firm’s 50-day moving average is $2.74 and its 200-day moving average is $2.32. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Sell-side analysts predict that Neumora Therapeutics will post -1.61 EPS for the current year.

Insider Activity at Neumora Therapeutics

In other news, insider Paul L. Berns sold 9,819 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total value of $34,464.69. Following the transaction, the insider owned 7,395,185 shares of the company’s stock, valued at approximately $25,957,099.35. This represents a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 23,387 shares of company stock valued at $82,647 over the last 90 days. 26.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Neumora Therapeutics

Several institutional investors have recently added to or reduced their stakes in NMRA. Hsbc Holdings PLC acquired a new position in Neumora Therapeutics in the 4th quarter valued at $27,000. Henson Edgewater Management LLC acquired a new stake in shares of Neumora Therapeutics during the fourth quarter worth $292,000. Virtu Financial LLC lifted its holdings in shares of Neumora Therapeutics by 465.7% during the fourth quarter. Virtu Financial LLC now owns 97,408 shares of the company’s stock worth $174,000 after buying an additional 80,189 shares in the last quarter. Invesco Ltd. boosted its position in shares of Neumora Therapeutics by 23.8% in the fourth quarter. Invesco Ltd. now owns 227,594 shares of the company’s stock valued at $407,000 after acquiring an additional 43,795 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $204,000. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics News Summary

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: Major firms reaffirmed buy ratings with large price targets—Guggenheim set a $14 target (very large upside) which boosts investor optimism about long‑term value. Guggenheim Reaffirms Buy, $14 PT
• Positive Sentiment: Needham also reaffirmed a buy rating and set an $8 price target, reinforcing analyst backing for NMRA’s pipeline recovery potential. Needham Reaffirms Buy, $8 PT
• Positive Sentiment: Company press release and earnings-call highlights emphasize a strong balance sheet and positive early NMRA‑511 data (claimed effect comparable to marketed agents in a prespecified population), which supports upside if later trials confirm signals. Q4 Results & NMRA-511 Data Release
• Neutral Sentiment: Unusually large options buying (roughly 2,812 calls vs. a daily average ~687) and elevated share volume indicate speculative/levered interest that can amplify moves in either direction.
• Negative Sentiment: The company disclosed a Nasdaq delisting risk that could impair liquidity, shareholder value and future capital access—this raises a material tail‑risk for investors. Nasdaq Delisting Risk Disclosure
• Negative Sentiment: Analyst downgrades and caution followed the KOASTAL‑1 failure (navacaprant) in MDD—this clinical setback and the uncertainty around upcoming KOASTAL‑2/3 readouts weigh on near‑term sentiment. SeekAlpha: Downgrade After Navacaprant Setback
• Negative Sentiment: Q4 EPS missed consensus by $0.01 (reported -$0.35 vs. -$0.34), a small miss but relevant given the company is not yet profitable; adds short‑term pressure on valuation. Earnings Release / Transcript

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.